3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
7
Small Cell Lung Carcinoma
6
Fallopian Tube Neoplasms
4
Lung Neoplasms
3
Sarcoma, Ewing
2
Neuroblastoma
2
Neoplasm Metastasis
2
Central Nervous System Neoplasms
2
Wilms Tumor
1
Uterine Cervical Neoplasms
1
SCLC
1
Rhabdoid Tumor
1
Pleuropulmonary blastoma
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasms
1
Ganglioneuroblastoma
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Endometrial Neoplasms
1
Choroid Plexus Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Neuroendocrine
1
Interventions
pembrolizumab
7
Specimen Handling
6
Human Papillomavirus DNA Tests
4
Colposcopy
4
Paclitaxel
3
Magnetic Resonance Spectroscopy
3
Fulvestrant
3
Cisplatin
3
Carboplatin
3
palbociclib
2
lenvatinib
2
Surveys and Questionnaires
2
Radiation Dose Hypofractionation
2
Nivolumab
2
Magnetic Resonance Imaging
2
Gemcitabine
2
Biopsy
2
Bevacizumab
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
tisotumab vedotin
1
sapanisertib
1
ribociclib
1
relatlimab
1
pertuzumab
1
patritumab deruxtecan
1
osimertinib
1
omipalisib
1
liposomal doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
Topotecan
×
30 days
×
Clear all
NCT06459180
2026-05-27
TroFuse-020
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
686 enrolled